Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rhythm Pharmaceuticals and keeping the price target at $105.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors, including the strong early adoption of IMCIVREE in hypothalamic obesity and the company’s ability to modestly exceed revenue expectations in 1Q26. He highlights that initial uptake in acquired hypothalamic obesity is running at a multiple of the early Bardet-Biedl syndrome launch, reinforcing confidence in sustained prescription growth and supporting his unchanged $105 price target.
Selvaraju also emphasizes the incremental upside from international expansion, with a staged European launch underway following recent regulatory approval and a potential Japanese approval decision expected in the second half of 2026. While Japanese sales are not yet incorporated into his financial model, the existing commercial infrastructure and sizable local patient population suggest future revenue optionality that is not fully reflected in the current valuation, further justifying his Buy recommendation.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 23.4% and a 54.60% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Aclaris Therapeutics, and Galderma Group AG.
In another report released on May 8, Stifel Nicolaus also maintained a Buy rating on the stock with a $133.00 price target.